A Potential COVID Vaccine Isn't the Only Reason CSX Stock Rallied 14.1% in November
Shares of CSX (NASDAQ: CSX) rallied 14.1% in the month of November, according to data provided by S&P Global Market Intelligence. While positive developments around a coronavirus vaccine triggered buying activity in transportation stocks, including airlines and railroads, the stamp of approval from a leading bank's research arm further fueled investor optimism in CSX stock. Despite an 11% drop in year-over-year revenue, CSX's operating ratio remained intact at 56.9%.
